The Emerging Role of Photobiomodulation in COVID-19 Therapy
A groundbreaking paper in the Medical Research Archives of ESMED
Applied BioPhotonics Ltd. is excited to announce the recent publication of the most comprehensive report on the treatment of acute and long COVID-19 through photobiomodulation (PBM) ever made. This groundbreaking report is supported by compelling evidence from independent case studies conducted by doctors, hospitals, and clinics in the USA and Taiwan, as well as an exhaustive review of existing literature.
Published in the distinguished peer-reviewed journal Medical Research Archives of the European Society of Medicine (ESMED), the two-part paper discusses the successful treatment of over 350 acute and long COVID-19 cases worldwide using photobiomodulation as both a primary modality and as an adjunctive therapy.
To access these papers, please download them from ESMED:
This extensive research effort encompasses numerous peer-reviewed publications on COVID-19 PBM, incorporating computer simulations, patient data, and over five-hundred cited references. The resulting 82-page compendium provides an invaluable repository of new medical case data and analysis, consolidating and corroborating findings from the previously acclaimed report, “Whole-organ transdermal photobiomodulation (PBM) of COVID-19: A 50-patient case study,” published in the Journal of BioPhotonics.
Providing a deep dive into the etiology of a SARS-CoV-2 infections, the paper chronicles disease progression from airway epithelial cells (AEC) in the sinuses and lungs leading to hyperinflammation of the bronchia and endothelia, followed by viremic spread into viscera and the neuroendocrine system, especially into tissue populated by a preponderance of ACE-2 receptors. The papers also detail the anti-infective mechanisms of photobiomodulation and its paradoxical ability to impede viral replication by stimulating innate immune response while concurrently limiting COVID’s characteristic hyperinflammation.
The work identifies the importance of early PBM intervention to shorten the severity and duration of a SARS-CoV-2 infection and to prevent the onset of long COVID. Furthermore, it highlights the distinction of acute COVID-19 as a inflammatory respiratory and circulatory disease. This is in contrast to long COVID, which manifests as diverse of neurological conditions (such as brain fog, neuralgia, and headache), and metabolic COVID-19, which impacts digestive, immune, neuroendocrine, and reproductive organs and tissue. The papers detail different PBM protocols tailored to address these varied presentations.
The prognosis of the treatment of both acute and long COVID-19 and other multi-stem inflammatory diseases using whole-organ deep-tissue photobiomodulation is highly encouraging, with 346 out of 350 patients exhibiting favorable outcomes. Most acute COVID-19 patients showed significant improvement within three days of treatment and achieved full recovery within two weeks, demonstrating normal CRP levels, no lung damage, and no requirement for supplemental oxygen.